International Assets Investment Management LLC Takes $259,000 Position in Glaukos Co. (NYSE:GKOS)

International Assets Investment Management LLC bought a new stake in shares of Glaukos Co. (NYSE:GKOS) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,259 shares of the medical instruments supplier’s stock, valued at approximately $259,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. CWM LLC lifted its position in shares of Glaukos by 309.5% during the 3rd quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,046 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Glaukos by 17.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $137,000 after purchasing an additional 270 shares in the last quarter. Mackenzie Financial Corp purchased a new position in Glaukos in the 3rd quarter valued at $203,000. Xponance Inc. purchased a new position in Glaukos in the 3rd quarter valued at $208,000. Finally, Pathstone Family Office LLC purchased a new position in Glaukos in the 3rd quarter valued at $217,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Down 0.6 %

Shares of GKOS opened at $99.48 on Friday. The firm has a market cap of $4.99 billion, a P/E ratio of -35.78 and a beta of 1.08. Glaukos Co. has a 12-month low of $45.38 and a 12-month high of $103.66. The company’s 50-day moving average price is $92.42 and its 200 day moving average price is $81.74. The company has a current ratio of 5.34, a quick ratio of 4.78 and a debt-to-equity ratio of 0.77.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.07). The company had revenue of $82.40 million during the quarter, compared to analysts’ expectations of $81.00 million. Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The firm’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.53) earnings per share. On average, sell-side analysts forecast that Glaukos Co. will post -2.18 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GKOS. StockNews.com lowered Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, February 27th. Wells Fargo & Company raised their price objective on Glaukos from $83.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, February 22nd. Stifel Nicolaus restated a “buy” rating and issued a $110.00 price objective on shares of Glaukos in a report on Wednesday, April 3rd. Truist Financial reaffirmed a “buy” rating and issued a $110.00 target price on shares of Glaukos in a research note on Monday, April 8th. Finally, Needham & Company LLC raised their target price on Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.80.

Insider Activity at Glaukos

In related news, CFO Alex R. Thurman sold 434 shares of the business’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $95.33, for a total value of $41,373.22. Following the sale, the chief financial officer now directly owns 54,166 shares in the company, valued at approximately $5,163,644.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Glaukos news, CFO Alex R. Thurman sold 434 shares of the business’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $95.33, for a total transaction of $41,373.22. Following the sale, the chief financial officer now directly owns 54,166 shares in the company, valued at $5,163,644.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joseph E. Gilliam sold 9,476 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $94.12, for a total transaction of $891,881.12. Following the sale, the chief operating officer now owns 119,802 shares in the company, valued at $11,275,764.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 242,357 shares of company stock worth $22,857,372. Company insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.